The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Actym Therapeutics; Aduro Biotech; Akrevia Therapeutics; Alphamab; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Benevir; Bristol-Myers Squibb; Compugen; Eisai; EMD Serono; IDEAYA Biosciences; Immunocore; Incyte; Janssen; Jounce Therapeutics; Leap Therapeutics; Mavu Pharmaceutical; Merck; Mersana; Novartis; Partner Therapeutics; Reflexion Medical; Spring Bank; Synlogic; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Akrevia Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Immunocore; Janssen; Jounce Therapeutics; Merck; Mersana; Novartis; Reflexion Medical
Manish R. Patel
Honoraria - Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Janssen; Regeneron
Speakers' Bureau - Janssen Oncology; Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Rgenix (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Regeneron
Susanna Varkey Ulahannan
Consulting or Advisory Role - Bayer; Exelixis; Incyte
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst); Tesaro (Inst)
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Shakeela Wazeen Bahadur
No Relationships to Disclose
Philip R. Clingan
No Relationships to Disclose
Girish Mallesara
No Relationships to Disclose
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
Scott Currence
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Linzhi Xu
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Sanjeev Kaul
Stock and Other Ownership Interests - Abbott; Abbvie; Baxter; Boston Scientific; Bristol-Myers Squibb; CVS; Johnson & Johnson; Medtronic; Merck; Walgreens
Consulting or Advisory Role - Bristol-Myers Squibb; Macrogenics; PharmaEssentia
Travel, Accommodations, Expenses - PharmaEssentia
Francine Chen
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Paul A. Moore
Stock and Other Ownership Interests - GlaxoSmithKline; Medtronic
Patents, Royalties, Other Intellectual Property - Have patents based on work at MacroGenics, Human Genome Sciences and Celera
Ezio Bonvini
Employment - Macrogenics
Leadership - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Patents, Royalties, Other Intellectual Property - Patent application and issued patents held by the US Federal Government (I); Patent applications and issued patents held by MGNX
Brad Sumrow
Employment - Macrogenics
George Blumenschein
Employment - Johnson & Johnson/Janssen (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; MedImmune; Merck; Novartis; Roche; Xcovery
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Immunocore (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Tmunity Therapeutics, Inc. (Inst); Torque (Inst); Xcovery (Inst)